Efficacy of Chinese herbal medicine on health-related quality of life (SF-36) in hypertensive patients: A systematic review and meta-analysis of randomized controlled trials

Jiao, Huachen; Ju, Jianqing; Li, Yunlun; Ma, Xuesheng; Jiang, Haiqiang; Zhao, Jing; Shen, Zhenxing; Yang, Wenqing

doi:10.1016/j.ctim.2015.04.002

Cited by 5 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, preliminary surveys revealed that there was an absence of studies on the anti-inflammatory effects of CHM in PWH to enable a systematic review or meta-analyses to be performed to address this question. Most current meta-analyses either focused on CHM for the treatment of AIDS ( 60 ) or investigated the effects of CHM with or without co-interventions on CVD management, but their favorable outcomes were blood lipid profiles ( 61 ), quality of life ( 62 ) or other specific parameters of the investigated conditions (e.g., blood pressure) ( 63 ), and not inflammatory biomarkers. The available studies were not sufficient to conduct a systematic review: only two RCTs and one parallel controlled study were returned after a comprehensive search of English and Chinese databases.…”

Section: Discussionmentioning

confidence: 99%

Effects and safety of Chinese herbal medicine on inflammatory biomarkers in cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials

Zhou²,

Trevillyan³

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Inflammation drives cardiovascular disease (CVD) in individuals with underlying chronic inflammatory diseases, including People with HIV (PWH), independently of dyslipidemia. Adjunctive treatments that lower inflammation may be useful to lower CVD risk in such populations. There is very little data on the efficacy of Chinese herbal medicine (CHM) in reducing inflammation in PWH to address its potential in reducing this CVD risk factor, therefore we evaluated its impact on inflammatory biomarkers relevant to CVD risk in the general population. Six English and Chinese databases were searched for studies investigating CHM’s effects on inflammatory biomarkers relevant to CVD from respective inceptions to February 2022. A systematic review and meta-analysis of randomized controlled trials (RCTs) were conducted and the most-frequently prescribed herbs were identified. Thirty-eight RCTs involving 4,047 participants were included. Greater than or equal to 50% of included studies had a low risk of bias in five domains (random sequence generation, detection, attrition, reporting and other bias) and 97% had a high risk of performance bias. CHM provided significant additive effects on attenuating relevant inflammatory indices including hs-CRP (SMD −2.05, 95% CI −2.55 to −1.54), IL-6 (SMD −1.14, 95% CI −1.63 to −0.66) and TNF-α levels (SMD −0.88, 95% CI −1.35 to −0.41), but no significant effects on hs-CRP were found between CHM and placebo when co-treating with Western drugs (MD 0.04, 95% CI −1.66 to 1.74). No severe adverse events were reported in CHM groups. The two most prevalent herbs present in formulae demonstrating reduction of at least one inflammatory biomarker were Dan shen (Salviae Miltiorrhizae Radix et Rhizoma) and Huang qi (Astragali Radix). CHM, in combination with standard anti-inflammatory medications, may depress inflammation and reduce the risk of inflammatory conditions such as CVD. Rigorously-conducted trials and adequate reporting are needed to provide more robust evidence supporting the use of CHM to reduce CVD risk in people with underlying chronic inflammation such as PWH.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects and safety of Chinese herbal medicine on inflammatory biomarkers in cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials

Zhou²,

Trevillyan³

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Quality of life (QOL) assessment is an important indicator of health status and the effectiveness of intervention measures. The Short Form Health Survey (SF‐36) is widely used to evaluate QOL of hypertension [ 27 ], but symptoms and side effects specific to hypertension are not included. Quality of Life Instruments for Chronic Diseases (QLICD) were developed and validated by Wan [ 15 ] by combining the general module (QLICD‐GM) with the specific module for hypertension.…”

Section: Discussionmentioning

confidence: 99%

Assessment of chronic disease management mode (CDMM) on participants with primary hypertension

Ling

Chen

et al. 2021

Tropical Med Int Health

View full text Add to dashboard Cite

objective Hypertension requires continuous and long-term care to prevent associated complications. Chronic disease management mode (CDMM) was developed to improve patients' selfmanagement. We aimed to evaluate quality of care and clinical outcomes of CDMM versus routine care.methods 300 patients aged >30 years with primary hypertension were randomly allocated to the CDMM intervention group (n = 162) or the usual care control group (n = 138). CDMM comprised nursing consultations, telephone contact, online WeChat link, health education, and appropriate referrals during hospitalisation and after discharge. QLICD-HY (V 2.0) scale was used to evaluate the quality of life. Care outcomes were biochemical parameters, body mass index, blood pressure levels, waist circumference, psychological indicators and quality of life assessed on admission (baseline) and one month post-care for both groups. Data were collected and analysed using SPSS 20.0.results After one month, the intervention group had 6 mm Hg (95% CI: −5.12 to −9.08) lower SBP and 0.6 mM/L (95% CI: −0.52 to −0.68) lower LDL than the control group. In terms of improvements in BMI, UmAlb or waist circumference, there were no differences between both groups. The intervention group scored better on psychological indicators than controls (P < 0.05), and scores reflecting social and psychological function in the intervention group were significantly higher than scores at baseline, and higher than scores of controls after one month (P < 0.05). In the control group, there was no statistically significant difference between the scores at baseline and after one month.conclusions Under CDMM hypertension care, improvement of blood pressure and LDL was clinically significant. Intervention care further improves social and psychological function among participants with primary hypertension. keywords chronic disease management mode, systolic blood pressure, QLICD-HY, primary hypertension, nurse Sustainable Development Goals: Good health and well-beingThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Mental health benefits of traditional Chinese medicine – An umbrella review of meta-analyses

Rodrigues

Santos

Ribeiro

et al. 2023

Brain Behavior and Immunity Integrative

View full text Add to dashboard Cite

Efficacy of Chinese herbal medicine on health-related quality of life (SF-36) in hypertensive patients: A systematic review and meta-analysis of randomized controlled trials

Cited by 5 publications

References 31 publications

Effects and safety of Chinese herbal medicine on inflammatory biomarkers in cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials

Effects and safety of Chinese herbal medicine on inflammatory biomarkers in cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials

Assessment of chronic disease management mode (CDMM) on participants with primary hypertension

Mental health benefits of traditional Chinese medicine – An umbrella review of meta-analyses

Contact Info

Product

Resources

About